This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stone, W. M. Articles by Money, S. R. Search for Related Content PubMed PubMed Citation Articles by Stone, W. M. Articles by Money, S. R. Social Bookmarking                         What's this?

The New Anticoagulants

Divisions of Vascular Surgery, Mayo Clinic Arizona, Scottsdale Arizona, Stone.William{at}mayo.edu

Britt H. Tonnessen, MD

Divisions of Vascular Surgery, Mayo Clinic Arizona, Scottsdale Arizona

Samuel R. Money, MD

Ochsner Clinic, New Orleans, Louisiana

Currently, the anticoagulants available are limited to warfarin, heparin compounds, and direct thrombin inhibitors. Warfarin, the most commonly used outpatient anticoagulant, has significant shortcomings. There are numerous drug/drug and drug/food interactions, and there is difficulty in dosing for one-third of patients. Numerous new anticoagulants are undergoing testing. The meta-pentasaccharides use the core molecule of heparin and replace one or more of the sulphated groups. They are administered by subcutaneous injection, but they require only once per week dosing. Numerous studies have shown equivalents or superiority to warfarin in treatment for thromboembolic events.

Direct thrombin inhibitors block thrombin (IIa) and are used mostly for heparin-induced thrombosis or during coronary interventions. However, there is an orally administered direct thrombin inhibitor, Dabigatran, which is undergoing phase III testing. It can be given without regard to weight, age, or gender with minimal drug interactions. This drug has been proven to be equivalent to low molecular weight heparin (LMWH) in deep venous thrombosis (DVT) prophylaxis and showed no excess bleeding.

Another promising group of anticoagulants with numerous investigations underway are the direct X inhibitors. Most are excreted renally as opposed to hepatic clearance with intravenous or oral dosing. Numerous phase II studies have shown them to have equivalent or superior prophylaxis for DVT when compared with LMWH. Oral IXa inhibitors and an oral thrombin cofactor inhibitor are also under development. It is clear that in the near future, anticoagulants will be available that offer significant advantages when compared to those currently in use.

Key Words: anticoagulants • metapentasaccharides • fondaparinux • idraparinux • direct thrombin inhibitors • ximelagatran

Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 19, No. 3, 332-335 (2007)
DOI: 10.1177/1531003507304441


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?